chemicals
Commented by Stefan Feulner on June 21st, 2023 | 07:20 CEST
Lanxess, Smartbroker, Helma Eigenheimbau - Great opportunities in uncertain times
The stock market is still defying negative omens such as recession, the strict monetary policy of the central banks and escalating geopolitical risks. Just a few days ago, for example, the German leading index DAX recorded a new all-time high. However, the negative voices concerning significant global stock market setbacks are increasing. Nevertheless, some companies have the potential to significantly outperform the market due to special situations.
Read
Commented by Fabian Lorenz on June 7th, 2023 | 08:00 CEST
Commodity shares with price potential: Bayer, K+S, and Almonty Industries in the analyst check
There are no signs of a deep recession in the US at the moment, which is positive for commodity prices and the corresponding companies. What do analysts say? They see a price potential of over 170% for tungsten producer Almonty Industries. With the commissioning of the flagship mine in South Korea, revenues and profits should increase strongly from 2024. After K+S earned brilliantly last year, there is a lack of positive impulses this year. Several analysts have spoken out. Can the DAX-listed company make gains again? At Bayer, the euphoria surrounding the change in the board of directors has faded, and the share price is almost back to where it was at the beginning of the year. But analysts see significant upside potential.
Read
Commented by Nico Popp on May 18th, 2023 | 09:30 CEST
Climate protection as an investment: BASF, Commerzbank, GoviEX Uranium
Fewer CO2 emissions, more climate protection. Every DAX-listed company is committed to more sustainability in some form or another. But what is the truth of these promises? And are the supposed climate shares a sustainable investment at all? We do the check and take a detailed look at three exciting stocks from different sectors and regions.
Read
Commented by Fabian Lorenz on May 4th, 2023 | 08:10 CEST
Buy or sell? TUI, BASF and Defence Therapeutics
BASF share a buy or sell? Analyst opinions on the chemical giant diverge widely. The DAX-listed company has just reported quarterly figures, but it did not provide clarity about the prospects. However, some speculate on a forecast increase. Analysts have not commented on TUI for quite some time. After the turbulence surrounding the capital increase, new impulses are being sought, perhaps through a deal with the German government? There is plenty of impetus for rising prices at Defence Therapeutics. The biotech high-flyer of the past months is increasingly positioning itself as a partner to BioNTech, Moderna and Co - and perhaps even a takeover candidate.
Read
Commented by Nico Popp on March 29th, 2023 | 08:15 CEST
Market failure! Highs and lows at BASF, Myriad Uranium, Vonovia
We all know efficient markets from the textbook. There, buyers and sellers always come together - and in the end, there is no apple left over. In reality, markets are highly complex and are sometimes dependent on external factors that can change everything overnight. Today we look at BASF's business in China, the real estate market and the emerging market for uranium.
Read
Commented by Fabian Lorenz on March 8th, 2023 | 16:22 CET
Nel share slumps, a 60% chance with Bayer, Almonty Industries and BASF
The Nel share was one of the big daily losers yesterday. As a result, the upward trend has finally been broken, and analysts' opinions differ widely. Berenberg sees the BASF share as a hold after the publication of the quarterly figures. The price target is EUR 55. The figures are in line with expectations. However, the end of share buybacks and concerns about future competitiveness weigh on the stock. By contrast, analysts see up to 60% upside potential for Bayer. Almonty Industries is benefiting from the boom in electromobility and also defense spending. As the leading tungsten producer outside China, analysts suspect it could soon come to a bidding war.
Read
Commented by Juliane Zielonka on March 3rd, 2023 | 10:00 CET
Rheinmetall, Defense Metals, BASF - Rearmament in the defense industry, restructuring in the chemical industry
A new chapter can begin for Ukraine's defense. Rheinmetall will supply the country with border surveillance technology. Analysts raise the share price target from EUR 240 to EUR 300. A solution to the conflict with Russia is not in sight, so demand for rare metals urgently needed in armaments is rising all the higher. This is where Defense Metals comes into play. The Canadian explorer has initial data from the crushing samples and can now better estimate the costs for the feasibility study. BASF is also concerned with costs. The Company put its red pen to work and cut 2/3 of its jobs, especially at a site in Germany. A planned agar project in the US has also been suspended until further notice.
Read
Commented by Juliane Zielonka on February 15th, 2023 | 12:01 CET
Altech Advanced Materials, Volkswagen, BASF - Innovative strength pushes growth
In the hunt for the precious raw materials needed for the energy transition, carmaker Volkswagen now has Canada on its radar. There, the Company wants to extract the lithium it so urgently needs for electric batteries. The Company would do well to reorganize its supply chains, and the EU is pushing for a CO2-friendly transformation of the automotive industry. The Company Altech Advanced Materials promises a higher performance of electric batteries. Its innovative technology allows electric batteries to perform better, which is ideal for the energy turnaround demanded by politicians. Chemical giant BASF is experiencing that politics cannot always be to the advantage of its own company. Once again, it is the EU that wants to ban a product...
Read
Commented by Fabian Lorenz on January 25th, 2023 | 13:54 CET
Bayer shares soon to reach triple digits? Barrick Gold and Desert Gold praised by analysts
Will Bayer be broken up, or will triple-digit share prices beckon? According to media reports, more and more investors are calling for the former. Most recently, Bluebell Capital Partners. According to the Bloomberg news agency, the British investor is calling on the DAX-listed Company to separate its Crop Science and Pharmaceuticals divisions. This could lead to a 70% increase in value for shareholders. Analysts also see considerable share price potential and believe that triple-digit prices are possible. Gold is also shining again. However, this has yet to be realized by exploration companies in particular. Experts see the chance of a revaluation at Desert Gold, for example - through takeover fantasy and drilling results. Besides B2Gold, Barrick Gold also comes into question as a buyer. The industry leader is also recommended as a buy, despite weakening Q4 results.
Read
Commented by Fabian Lorenz on December 21st, 2022 | 08:48 CET
BASF, BioNTech, Cardiol Therapeutics: Stocks for 2023?
Is there a 400% upside potential in 2023? At the end of a challenging 2022 stock market year, we are looking ahead to the new year. Which share is worth buying, and which is better left alone? In the case of BASF, the high dividend yield is one of the attractions. The latest company news shows that the chemical group is also involved in the mega market of electromobility. But the dependence on gas supplies is causing uncertainty, and an analyst has renewed a sell recommendation for BASF shares. BioNTech, on the other hand, is looking good, even if the chart picture has recently clouded over. The development pipeline is full, capacities - especially in Asia - are being expanded, and analysts are also more courageous again. Investors also need a little courage and, above all, patience with Cardiol Therapeutics. They could soon be rewarded. The cash position of the biotech pearl is almost equal to the market capitalization, the main product is already in the Phase 2 pilot study, and analysts see massive upside potential.
Read